Imperial Science Café: Lighting the way to better breast cancer surgery? скачать в хорошем качестве

Imperial Science Café: Lighting the way to better breast cancer surgery?

Imperial Science Cafes have been hosted by the Imperial Cancer Research UK Centre for a decade at Maggie’s West London. They have given our researchers the opportunity to have an ongoing conversation with patients and the public around cancer research. These events have, in the past, been face to face events but during social distancing, we have decided to bring these events to an online platform. The presentations are aimed at a lay audience, the presenter(s) share their research for 20-30 mins and the remainder of the time is for questions and discussion with the audience. This event will showcase research relating cancer surgery. Lighting the way to better breast cancer surgery? Maria Leiloglou and Marta Kedrzycki Maria Leiloglou is a 3rd year PhD student at the Hamlyn Centre for Surgical Robotics in the Department of Cancer & Surgery at Imperial College London. Martha Kedrzycki is a clinical research fellow in translational breast cancer surgery and is also in her 3rd year of her PhD at Imperial College London. Maria and Marta are working on fluorescence guided surgery in breast cancer. In our research, we use a fluorescent drug which targets/marks breast cancer, and then can essentially ‘light up the tumour’ in the infrared (not visible) spectrum. This helps the surgeon see where it is, how big it is, and how invasive it is in real-time on a visual display. The reason this is so important is because right now surgeons are limited to preoperative imaging or what they can see and feel during the surgery to guide them, which unfortunately is inadequate in about 20% of breast conserving operations (where they just take the lump out) and results in women needing another surgery. Using special image pattern analysis, Maria has been able to find significant differences between the cancer and normal tissue, to help make this technique more accurate and therefore clinically viable.